Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease
NCT03865407Phase 2Terminated
- Sponsor
- Virginia Commonwealth University
- Start
- Mar 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of allopurinol in chronic kidney disease (CKD) and hyperuricemia (2 arms), sponsored by Virginia Commonwealth University. Primary endpoints: Estimated Glomerular Filtration Rate Change (Cystatin C) at 6 months and Estimated Glomerular Filtration Rate Change (Creatinine) at 6 months. Started Mar 2019; status: terminated.
02
Drugs
allopurinol
03
Conditions
chronic kidney disease (CKD)hyperuricemia
Beyond the preview
Go deeper on NCT03865407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03865407.